Galvani Bioelectronics
{{Short description|United Kingdom company}}
{{Use dmy dates|date=April 2022}}
{{Infobox company
| name = Galvani Bioelectronics
| logo = Galvani Bioelectronics logo.png
| type = Subsidiary
| industry = Bioelectronics
| parent = GlaxoSmithKline (55% equity interest)
| homepage = {{URL|http://galvani.bio}}
| foundation = November 2016{{cite web|title=Galvani Bioelectronics Website|url=http://www.galvani.bio/|website=Galvani Bioelectronics|accessdate=24 December 2016}}
| founders = {{unbulleted list|GlaxoSmithKline|Verily Life Sciences}}{{cite web|title=Galvani Bioelectronics|url=https://verily.com/projects/interventions/galvani-bioelectronics/index.html|website=Verily Life Sciences website|accessdate=24 December 2016}}
| key_people = Kristoffer Famm (President){{cite web|title=Kristoffer Famm Ph.D. - Galvani Bioelectronics|url=http://www.galvani.bio/people/kristoffer-famm-ph-d/|website=Galvani Bioelectronics|accessdate=25 December 2016}}
| location_city = Stevenage{{cite news|last1=Temperton|first1=James|title=GSK and Google just created a £540m bioelectronic health firm|url=https://www.wired.co.uk/article/galvani-bioelectronics-gsk-google-alphabet-verily|accessdate=24 December 2016|publisher=Wired|date=1 August 2016}}
| location_country = United Kingdom
}}
Galvani Bioelectronics is a Stevenage, United Kingdom-based{{Cite web|last=Kollewe|first=Julia|date=2017-08-28|title=Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline|url=https://www.theguardian.com/business/2017/aug/28/electroceuticals-bioelectronics-implants-glaxosmithkline-galvani-kris-famm|access-date=2018-08-03|website=the Guardian|language=en}} bioelectronics R&D company.
History
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016. The partnership to form the company was announced on 1 August 2016.
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner. The initial agreed upon investment between the two companies is up to £540 million over a period of seven years{{Cite web|url=https://worldanalytics24.com/bioelectric-medicine-market-focusing-long-term-professional-industry-and-making-new-commitments-to-the-sustainable-future-2018-2026/23817/|title=Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future|date=23 January 2019|website=Worldanalytics24.com|language=en-US|access-date=2019-01-31}} and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."{{Cite web|title=Galvani Bioelectronics|url=https://www.fiercebiotech.com/special-report/fiercemedicaldevices-2016-fierce-15-galvani-bioelectronics|access-date=2020-07-13|website=FierceBiotech|language=en}} Additionally, both companies agreed to contribute their existing intellectual property rights.
In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. {{Cite web |title=Verily Life Sciences |url=https://verily.com/blog/galvani-bioelectronics-reaches-major-milestone-in-ra-neuromodulation-therapy-with-first-patient-implantation/ |access-date=2017-02-15 |website=verily.com}}
References
{{Reflist}}
External links
- [https://www.gsk.com/en-gb/media/press-releases/gsk-and-verily-to-establish-galvani-bioelectronics-a-new-company-dedicated-to-the-development-of-bioelectronic-medicines/ Announcement by GSK]
Category:Biotechnology companies of the United Kingdom
Category:Companies based in Stevenage
Category:2016 establishments in England
Category:Biotechnology companies established in 2016
{{UK-company-stub}}